浸润性髓内星形细胞瘤WHO II-IV级的手术治疗与神经功能结局:多中心回顾性病例系列
该多中心回顾性研究纳入2008至2019年五家高容量神经外科中心治疗的40例WHO II-IV级恶性脊髓星形细胞瘤患者,排除毛细胞型星形细胞瘤,评估手术技术、围手术期神经状态、辅助肿瘤治疗及临床结局。结果显示中位总生存期在WHO II级为46.5个月、III级为25.7个月、IV级为7.4个月,术前临床状态与WHO分级显著影响总生存期,而切除程度未显著影响。
要点
- WHO II-IV级浸润性髓内星形细胞瘤预后差,中位OS随分级升高而缩短。
- 49%患者术后神经功能恶化,手术相关神经损伤发生率高。
- 手术目标宜限于活检获取组织学诊断,或对术前快速进展的重度 deficits 行肿瘤减容。
核心结论
- 浸润性髓内星形细胞瘤WHO II-IV级为罕见实体,预后不良。
- 因手术相关神经功能损害发生率高,手术目的应限于活检获取组织学诊断,或对术前快速进展的重度神经缺损行肿瘤减容。
- 术前临床状态与WHO分级显著影响总生存期,切除程度未显著影响总生存期。
研究设计与样本
- 多中心回顾性病例系列,纳入五家高容量神经外科中心2008至2019年治疗的脊髓恶性胶质瘤WHO II-IV级患者。
- 共纳入40例,其中弥漫性星形细胞瘤WHO II级11例、间变性星形细胞瘤WHO III级12例、WHO IV级17例;排除毛细胞型星形细胞瘤。
- 评估手术技术、围手术期神经状态、辅助肿瘤治疗及临床结局。
主要发现
- 术前仅40%患者功能独立,多数患者表现为中度残疾(47.5%)。
- 多数患者接受活检(n=18,45%)或次全肿瘤切除(n=15,37.5%),49%患者术后神经功能恶化。
- WHO III级和IV级肿瘤患者接受联合放化疗。
- 中位总生存期:WHO II级46.5个月,WHO III级25.7个月,WHO IV级7.4个月。
关键数值与推荐
- WHO III级和IV级肿瘤患者接受联合放化疗。
- 术前临床状态和WHO分级显著影响总生存期,切除程度未显著影响总生存期。
临床怎么用
- 对浸润性髓内星形细胞瘤WHO II-IV级,手术目标宜限于活检获取组织学诊断。
- 对术前快速进展的重度神经缺损患者,可考虑肿瘤减容。
- 术后根据WHO分级考虑辅助放化疗,WHO III级和IV级患者接受联合放化疗。
局限性
- 本研究为多中心回顾性研究,样本量有限(共40例)。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Primary malignant spinal astrocytomas present rare oncological entities with limited median survival and rapid neurological deterioration. Evidence on surgical therapy, adjuvant treatment, and neurological outcome is sparse. We aim to describe the treatment algorithm and clinical features on patients with infiltrating intramedullary astrocytomas graded WHO II-IV. METHODS: The following is a multicentered retrospective study of patients treated for spinal malignant glioma WHO II-IV in five high-volume neurosurgical departments from 2008 to 2019. Pilocytic astrocytomas were excluded. We assessed data on surgical technique, perioperative neurological status, adjuvant oncological therapy, and clinical outcome. RESULTS: 40 patients were included (diffuse astrocytoma WHO II n = 11, anaplastic astrocytoma WHO III n = 12, WHO IV n = 17). Only 40% were functionally independent before surgery, most patients presented with moderate disability (47.5%). Most patients underwent a biopsy (n = 18, 45%) or subtotal tumor resection (n = 15, 37.5%), and 49% of the patients deteriorated after surgery. Patients with WHO III and IV tumors were treated with combined radiochemotherapy. Median overall survival (OS) was 46.5 months in WHO II, 25.7 months in WHO III, and 7.4 months in WHO IV astrocytomas. Preoperative clinical status and WHO significantly influenced the OS, and the extent of resection did not. CONCLUSION: Infiltrating intramedullary astrocytomas WHO II-IV present rare entities with dismal prognosis. Due to the high incidence of surgery-related neurological impairment, the aim of the surgical approach should be limited to obtaining the histological tissue via a biopsy or, tumor debulking in cases with rapidly progressive severe preoperative deficits.
引用
- Butenschoen VM, Hubertus V, Janssen IK, et al. Surgical treatment and neurological outcome of infiltrating intramedullary astrocytoma WHO II-IV: a multicenter retrospective case series. J Neurooncol. 2020. PMID: 33094355. doi:10.1007/s11060-020-03647-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。